According to a Cancer Research UK funded study published in Cancer Cell,combining two different immunotherapy treatments could dramatically improve lymphoma survival.
Researchers from the University of Southampton tested different combinations of antibodies in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.
Follicular Lymphoma
Follicular lymphoma is a slow growing cancer of the lymph nodes. It is the most common form of slow growing B-cell non-Hodgkin's lymphoma.
Advertisement
‘When combined, the researchers found the antibodies recruit greater numbers of immune cells called myeloid cells, as well as increasing their ability to destroy cancer cells.’
Tweet it Now
They found one combination - anti-CD27 and anti-CD20 - greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.
As a direct result of this study, the combination will now be tested in patients as part of a clinical trial funded by Cancer Research UK.
Dr Sean Lim, a Cancer Research UK clinician scientist at the University of Southampton, said: "By combining two specific antibodies - anti-CD27 and anti-CD20 - we've increased the ability of the immune system to destroy cancer cells.
![Hodgkins Lymphoma]( "Hodgkins Lymphoma")
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by chemotherapy or by radiotherapy.
"It's very exciting to see that this drug combination has an impact on survival of mice with lymphoma, as improvements in treatment are urgently needed. The next stage will be to see if what we've discovered can be replicated in patients."
Professor Karen Vousden, Cancer Research UK's chief scientist, said: "This study greatly increases our understanding of how different immunotherapies can work together to improve the way we treat lymphoma.
"By testing this approach in a clinical trial we will see if this promising research will translate into benefit for patients."
Source: Eurekalert
Dr Sean Lim, a Cancer Research UK clinician scientist at the University of Southampton, said: "By combining two specific antibodies - anti-CD27 and anti-CD20 - we've increased the ability of the immune system to destroy cancer cells.
Hodgkins Lymphoma
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by chemotherapy or by radiotherapy.
Advertisement
"It's very exciting to see that this drug combination has an impact on survival of mice with lymphoma, as improvements in treatment are urgently needed. The next stage will be to see if what we've discovered can be replicated in patients."
Professor Karen Vousden, Cancer Research UK's chief scientist, said: "This study greatly increases our understanding of how different immunotherapies can work together to improve the way we treat lymphoma.
"By testing this approach in a clinical trial we will see if this promising research will translate into benefit for patients."
Source: Eurekalert
AIDS-HIV-Cancer
AIDS defining malignancies are cancers that occur in patients with AIDS due to their low immunity.
Advertisement
 Chemotherapy DrugsChemotherapy drugs perform like 'magic bullets' to destroy cancer cells in the body. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.
Memory deficits in individuals with epilepsy, especially cognitive difficulties, might partially stem from the transient impairments caused by these slow waves.
High altitude training exhibits potential benefits for pre-surgery patients, enhancing readiness, stated a new study.
The AI method shows promise in identifying imaging biomarkers for diagnosing ADHD.